Welcome to our dedicated page for REVIVA PHARMACEUTICALS HOLDINGS SEC filings (Ticker: RVPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REVIVA PHARMACEUTICALS HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REVIVA PHARMACEUTICALS HOLDINGS's regulatory disclosures and financial reporting.
Reviva Pharmaceuticals Holdings, Inc. reports that its common stock will be delisted from the Nasdaq Capital Market after failing to meet Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2) by May 11, 2026.
The Nasdaq Hearings Panel notified the company on May 12, 2026 that trading on Nasdaq will be suspended as of the open on May 14, 2026. On the same date, the stock is expected to begin trading on the OTCQB Venture Market under the existing symbol “RVPH.”
The company adds new risk disclosures explaining that the Nasdaq delisting and OTCQB trading may reduce liquidity and market price, limit access to capital and equity incentives, subject the stock to “penny stock” rules, and increase volatility and difficulty for investors seeking to resell shares.
UBS Group reports shared ownership of 746,095 shares (5.82%) of Reviva Pharmaceuticals Holdings, Inc. The Schedule 13G discloses that UBS Group and certain wholly owned subsidiaries hold 746,095 shares of common stock, with shared voting and dispositive power over those shares. The filing lists UBS Group's principal office in Zurich and identifies the securities by CUSIP 76152G209. The form is signed by a director on 05/07/2026 and indicates the ownership amount as of 03/31/2026.
Reviva Pharmaceuticals Holdings provided shareholders with an update on its lead drug brilaroxazine and its financial position. The company is pursuing a new composition of matter patent on a revised form of brilaroxazine, aiming to extend potential commercial exclusivity, possibly through 2046, and plans to seek FDA alignment to use this new form in a second Phase 3 schizophrenia trial, RECOVER-2.
Reviva expects to start RECOVER-2 trial activities in Q2 2026, begin U.S. patient enrollment in Q3 2026, and complete the study in Q4 2027. The company also highlighted a recent $10 million financing, giving it about $23 million in cash and cash equivalents and an estimated cash runway into Q1 2027, while emphasizing that its business is heavily dependent on successful development and approval of brilaroxazine.
Reviva Pharmaceuticals Holdings, Inc. disclosed a joint Schedule 13G filing showing a group of filers—Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander—each reporting 793,952 shares, representing 6.2% of the class.
The filing states these shares are held by entities over which Millennium Management LLC and related managers have voting control and investment discretion. The submission includes a Joint Filing Agreement dated March 27, 2026 and lists the issuer CUSIP 76152G209.
Reviva Pharmaceuticals Holdings, Inc. reported full year 2025 results, highlighting progress toward late-stage development of brilaroxazine for schizophrenia. The FDA recommended a second Phase 3 trial, and Reviva plans to start the RECOVER-2 registrational study in mid-2026 as part of a future NDA package.
For 2025, Reviva posted a net loss of $19.9 million, improving from a $29.9 million net loss in 2024 as total operating expenses fell to $20.2 million from $30.8 million. Research and development expenses declined to $11.7 million, while general and administrative costs rose modestly to $8.5 million.
Cash and cash equivalents were $14.4 million as of December 31, 2025, slightly above the prior year. Stockholders’ equity increased to $8.6 million, supported by higher additional paid-in capital and a larger share count, with 5,872,865 common shares issued and outstanding at year-end.
Reviva Pharmaceuticals Holdings, Inc. files its annual report describing a late-stage CNS and inflammatory disease pipeline led by brilaroxazine for schizophrenia. The company reports positive results from a large Phase 3 RECOVER trial and a 12‑month extension showing durable efficacy and generally favorable safety.
FDA has asked Reviva to run an additional Phase 3 schizophrenia study (RECOVER‑2) using 30 mg and 50 mg doses before submitting a new drug application, with trial activities expected to start in 2026 and completion targeted for 2027. Brilaroxazine also holds orphan drug designations for pulmonary arterial hypertension and idiopathic pulmonary fibrosis and has encouraging preclinical data in both.
To support operations and development, Reviva executed a May 2025 at‑the‑market program and a March 2026 public offering, raising cash through common stock, pre‑funded warrants and common warrants. A 1‑for‑20 reverse stock split became effective in March 2026, and shares outstanding were 12,810,377 as of March 27, 2026.
Reviva Pharmaceuticals Holdings, Inc. Schedule 13G reports that CVI Investments, Inc. and Heights Capital Management, Inc. together beneficially hold 666,667 shares of common stock, representing 5.2% of the class. The filing states there were 12,727,044 Shares outstanding as of the completion of the offering per the Prospectus Supplement dated March 19, 2026. Heights Capital Management, Inc. is disclosed as investment manager to CVI Investments, Inc. and "may exercise voting and dispositive power" over the shares; the Reporting Persons disclaim beneficial ownership except for their pecuniary interest. The filing is signed by Sarah Travis on March 25, 2026.
Reviva Pharmaceuticals Holdings, Inc. investor Parag Saxena filed an amended Schedule 13D reporting beneficial ownership of 363,280 shares of common stock, or about 2.8% of the 12,810,377 shares outstanding as of March 20, 2026. His holdings include directly owned shares, interests held through various Vedanta-related entities, shares underlying warrants and pre-funded warrants, and fully vested options exercisable within 60 days of the filing date. The filing states that Saxena ceased to be a beneficial owner of more than five percent of Reviva’s common stock on March 20, 2026, and that he has not effected any transactions in the issuer’s securities during the 60 days preceding this amendment.
REVIVA PHARMACEUTICALS HOLDINGS, INC. Chief Financial Officer Prabhu Narayan received a grant of stock options covering 40,925 shares of common stock on the grant date of March 18, 2026. These options have an exercise price of $1.87 per share and expire on March 17, 2036.
The award vests over time under the company’s 2020 Equity Incentive Plan. Of the total, 12,789 option shares vested immediately on the grant date, while the remaining 28,136 shares will vest in equal monthly installments from April 2026 through December 2028, encouraging long-term alignment with the company.
REVIVA PHARMACEUTICALS HOLDINGS, INC. President and CEO Laxminarayan Bhat reported receiving two stock option awards under the company’s 2020 Equity Incentive Plan. The grants cover a total of 150,075 options to buy common stock at an exercise price of $1.87 per share, expiring on March 17, 2036.
One option for 109,150 shares is held directly and another for 40,925 shares is held indirectly through his spouse. For the direct grant, 34,110 options vest immediately and 75,040 vest in equal monthly installments from April 2026 to December 2028. For the spouse-held grant, 12,789 options vest immediately and 28,136 vest on the same monthly schedule. These are compensation-related awards, not open‑market share purchases or sales.